HIV Prevention with emtracitabine/tenofovir DF (Truvada®) across the Ochsner Hospital System

In 2014, Louisiana had the highest incidence rate of the human immunodeficiency virus (HIV) among states in the US, primarily in men who sleep with men (MSM). The Pre-Exposure Prophylaxis for HIV (PreP) with emtracitabine and tenofovir DF (pill brand name Truvada®), is highly effective in preventing HIV transmission in high-risk populations. In July 2012, the FDA approved Truvuda® for PreP with a Risk Evaluation and Mitigation Strategy (REMS) which includes training and education for prescribers to counsel individuals. Evaluating Ochsner providers' adherence to current recommended guidelines for prescribing PreP is important for identifying areas of improvement in clinical practice and monitoring to reduce new HIV infections.

Goals

• To retrospectively examine the clinical care of HIV negative patients who received PreP
• To compare characteristics of MSM who did and did not receive PreP during the study period

Principal Investigator:
G. Dodd Denton, MD

Co- Investigator:
Eboni G. Price-Haywood, MD, MPH, FACP